The Biden administration is proposing Medicare and Medicaid coverage for weight loss drugs Wegovy and Zepbound, potentially costing $35 billion over a decade. Amgen’s obesity drug, MariTide, showed promising results with 20% weight loss in a Phase 2 study, leading to questions about its competitiveness. The results suggest MariTide could outperform other drugs like Wegovy and Zepbound. Expectations are high for a Phase 3 study of MariTide. Overall, the proposal aims to reduce out-of-pocket costs for prescription drugs and extend coverage to millions of older adults. The administration’s plan could go into effect in 2026, with potential benefits for enrollees.
Source link
We’re reading about Medicare obesity coverage, a 340B analysis
